Oncology Resource Group (ONCrg) is an accomplished team of competitive intelligence professionals with strong scientific, clinical, and commercial proficiencies. Our analysts cultivate their unmatched expertise through continuous study of solid tumors, hematologic malignancies, and immuno-oncology to deliver unique, year-round competitive intelligence. ONCrg’s medical congress, competitive landscape, and surveillance reports provide unparalleled depth, breadth, and insight in each of our practice areas.
Lisa Komenda, Ph.D.
Therapy Area Director
Lisa received her doctorate in Molecular and Cell Biology from the University of California, Berkeley and has contributed content to our strategic, market research reports in a number of disease areas. Lisa serves clients with her strong scientific acumen, analytical aptitude and knowledge gained from her experience in early-stage regulatory consulting and in developing and implementing marketing strategies.
Carla Cabrera, Ph.D.
Disease Area Analyst, Oncology
Carla completed her postdoctoral fellowship at MedImmune/AstraZeneca after receiving her Ph.D. in Tumor Biology at Georgetown University. Her unique background combines experience in drug development and early discovery in pharma with business development, competitive intelligence, and market research in early-stage companies. Carla capitalizes on her industry experience and rigorous scientific training to provide valuable insights to clients.
Pricing and More Information:
Call: 650-485-2626
Visit: www.onc-rg.com
Email: michael.reynolds@onc-rg.com
ONCrg Conference™ delivers unrivaled competitive intelligence from major congresses. ONCrg’s syndicated model covers the entire Prostate Cancer landscape, but leaves room to add or drill down on your interests. Highly relevant reports capture key data and include our expert opinions about the implications of new data on your pipeline.
Competitive Landscape Analysis
ONCrg Pipeline Strategies™ delivers cutting-edge profiles across the entire Prostate Cancer competitive landscape, providing valuable analytics by class and treatment subset for new drugs in Phase I/II development and beyond. Reports are updated quarterly and written in two formats:
- a presentation format for higher level comparative analytics
- a corresponding compendium with additional detailed commentary from ONCrg experts
Monthly Surveillance Reports
ONCrg Sentinel™ provides vigilant monitoring of rapidly evolving scientific, clinical, and commercial activities in Prostate Cancer. ONCrg experts identify and analyze events to deliver incisive commentaries each month that inform subscribers and prepare them to respond wisely to changing market conditions.
Expert Advisory Guidance
ONCrg Advisory™ is an open door to ask non-proprietary questions in Prostate Cancer and your other subscription areas. Our experts utilize extensive resources and experience to provide extra guidance to inform clients’ key decisions.